Related posters
(Maxivax) Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells drives tumor response and prolongs survival in a colorectal cancer model
CTLA-4 & survival in a colorectal cancer model
April 14, 2023
Abstract
Systemic therapy with CTLA-4 blocking antibody (aCTLA4) restores endogenous anti tumor immunity and induces remarkable long-term clinical benefits in patients with melanoma. Yet immune-related side effects remain a major hurdle to extend its label to many more types of cancer. Intra- and peritumoral administration of aCTLA4 has recently emerged to optimize its dose/efficacy ratio while preventing its on-target, off-tumor systemic toxicities. Sustained delivery of low dose aCTLA4 by genetically engineered encapsulated cells (MVX-3) could offer a promising option for cancer treatment addressing the shortcomings of systemic therapy.
Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
Scientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Customer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Collaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate